

Quinazolinone-based hybrids with diverse biological activities: A mini-review

Rezvan Rezaeinasab¹, Elham Jafari², Ghadamali Khodarahmi³

¹Department of Medicinal Chemistry, School of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran, ²Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, ³Department of Medicinal Chemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Quinazolinone and quinazoline have been shown different pharmacological activities, namely anticancer, anti-inflammatory, anti-hyperlipidemia, analgesic, antihypertensive, and antibacterial. On the other hand, molecular hybridization is a structural modification technique in the design of new ligands which consist of two or more pharmacologically active molecules in one structure. Therefore, due to the importance of the biological activities of quinazolinones for the development of new therapeutic agents, this review emphasizes current findings on various quinazolinone-based hybrids in medicinal chemistry. Moreover, it highlights the biological activities and structure-activity relationship of these hybrids.

Key words: Biological activities, hybrid, quinazoline, quinazolinone, synthesis

How to cite this article: Rezaeinasab R, Jafari E, Khodarahmi G. Quinazolinone-based hybrids with diverse biological activities: A mini-review. *J Res Med Sci* 2022;27:68.

INTRODUCTION

The first quinazoline nucleus was synthesized by the reaction of anthranilic acid with cyanogens in 1869.^[1] After that, Gabriel synthesized quinazoline derivatives in 1903.^[2] Many years later, the synthesis of quinazolinone derivatives was done by the different methods such as Niementowski's synthesis, Grimmel, Guinther, and Morgan's synthesis.^[3,4] In the past decades, many scientists were synthesized quinazolinone nucleus by the different techniques.^[5-7] Due to the importance of these fused heterocyclic compounds, medicinal chemistry researchers had much attention in biological assay of the quinazoline/quinazolinone derivatives.^[8] Quinazolinone are nitrogenated scaffolds that were extensively gained much attention due to pharmacological activities, including anticancer,^[9-11] anti-inflammatory,^[12] antimicrobial,^[13,14] antihypertensive,^[15] dihydrofolate reductase (DHFR) inhibition,^[16] Tyrosine Kinase inhibition,^[17] etc. Molecular hybridization is a strategy

for designing hybrid compounds that two or more small molecules such as quinazolinone, thiazole, triazole, benzofuran, and imidazole covalent and noncovalent linked.^[18] These new hybrid molecules improved the pharmacological activity^[11] through interaction with biological targets such as aromatase, cyclooxygenase (COX), DHFR enzymes, and epidermal growth factor receptor (EGFR).^[9] There are diverse synthetic quinazoline-based drugs such as gefitinib and erlotinib (EGFR inhibitors), alfuzosin and prazosin (α 1 blockers), which are used in clinics [Figure 1].^[20,21] Hybrid compounds, including quinazolinone and other pharmacologically active heterocycles, have resulted in new chemical drugs with reduced multidrug resistance. The activity of quinazolinone-based hybrid derivatives has been demonstrated in some literature.^[22,23] This review focuses on the important biological activities of quinazolinone-based hybrids including anti-cancer, antibacterial, urease enzyme inhibition, COX enzyme inhibition, β -site amyloid precursor protein cleaving

Access this article online

Quick Response Code:



Website:

www.jmsjournal.net

DOI:

10.4103/jrms.jrms_1025_21

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Address for correspondence: Dr. Elham Jafari, Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

E-mail: jafari@pharm.mui.ac.ir

Submitted: 24-Nov-2021; **Revised:** 12-Feb-2022; **Accepted:** 04-Apr-2022; **Published:** 27-Sep-2022




Figure 1: Synthetic quinazolinone-based drugs in the clinic

enzyme 1 (BACE1) inhibition, dipeptidyl peptidase IV (DPP-4) inhibition and antimalarial activities, also the impact of different substituents on the biological activities were discussed in some compounds.

ANTI-CANCER ACTIVITIES

Piperazine is a significant heterocycle anchor for improving novel therapeutic compounds, in particular cytotoxic agents.^[24] Piperazine-1-carbothiyl and piperazine-1-carbodithioate derivatives have shown cytotoxicity against hepatocellular and gastric carcinomas. Hence, Zhang *et al.* reported two series of hybrid compounds, including quinazolinone and piperazine moiety. Then, these new compounds were assayed against MCF-7, A549, and HCT-116 cell lines. The structures (1–3) presented in Figure 2 inhibited the proliferation of three cancer cell lines with IC_{50} values $<10 \mu\text{M}$. These results revealed that replacing the cyclohexyl group with aliphatic or alkyl heterocycl groups decreased antiproliferative potency.^[25]

Among the various synthesized compounds of quinazolinones, 2-styryl quinazolinones, and 2-methyl quinazolinones derivatives showed pharmacologically active properties due to inhibitory effects on tubulin polymerization and DNA repair enzyme poly (Adenosine diphosphate-ribose) polymerase, respectively.^[26] More ever, pyrrolobenzodiazepines, a natural antibiotic, are associated with antitumor activity by interaction with double-stranded DNA and forming a covalent bond.^[27] In a hybridization strategy, these two pharmacophores were combined by Kamal *et al.* in good yield through different alkane spacers. Compounds 4 and 5 [Figure 2]. Compound 4 showed GI_{50} values of $<0.1 \mu\text{M}$ against 60 human cancer cell lines [Figure 2].^[28]

Vodnala *et al.* have designed new hybrid compounds that consist of dihydropyranochromene as a privileged oxa-heterocyclic unit at the C-2 position of quinazolinone ring. Final structures were prepared in a one-pot three-component synthesis. Then, these hybrids were assayed against the

breast cancer cell lines of MDA-MB 231 and MDA-MB 453. Compound 6 [Figure 2] with substitution chlorine and bromine at phenyl ring of oxa-heteroaryl scaffold found as an active molecule with IC_{50} values at $45.7 \mu\text{M}$ and $28.3 \mu\text{M}$ concentrations in MDA-MB453 and MDA-MB 231 cell lines, respectively. Molecular docking results of this structure into the receptor site of ER α protein (3UUD) showed the best docking score results. Bromo and chloro substituents in phenyl ring oriented toward the hydrophobic pockets cause a positive influence in binding affinity with protein.^[29]

In the research for developing more potent anticancer agents, Kamal *et al.* have modified podophyllotoxin structure using hybridization strategy. Some derivatives of podophyllotoxin-based quinazolinone were synthesized by stable alkane spacers and amide bonds. Some of these hybrids compound 7 have the potentiality to control breast cancer cell growth by affecting tumor angiogenesis and invasion [Figure 2].^[30]

Asadi *et al.* have synthesized a unique series of hybrid molecules by the connecting of quinazolinone, benzofuran, and imidazolium moiety, followed by the evaluation of their cytotoxic activity. Among the synthesized hybrids, compound 8 has reported the most potent cytotoxicity, with IC_{50} values of $0.59 \mu\text{M}$ against the MCF-7 cell line [Figure 2]. Structure-activity relationship (SAR) consideration declared the important role of the methoxy substituent on benzofuran ring in the growth inhibition. Furthermore, the results of the docking analysis of these hybrids to aromatase were paralleled with the results of the experimental study (PDB ID: 3EQM).^[31]

Alkylphospholipids have shown antitumor activities.^[32-35] Miltefosine and edelfosine are two essential antitumor lipids [Figure 2].^[36] On the other hand, erlotinib is a famous EGFR inhibitor.^[37] In the search for developing multitarget anticancer agents, Alam *et al.* reported two series of hybrid compounds. Antitumor phospholipid molecule via linking erlotinib as the pharmacophoric moiety (EGFR inhibitor) were prepared through an amide or ester group at the *sn*-2

position. Then, these new hybrids were assayed against four cell lines (A-549, MCF-7, HepG2, and A-431) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. In contrast with ester analogs, the amide series with long alkyl chain enhanced cytotoxic activity. Notably, compound 9 had the best efficacy against MCF-7 cell line than reference erlotinib and miltefosine [Figure 2].^[38]

Ghorab *et al.* synthesized benzenesulfonamide-linked benzo quinazolinone-based hybrids as dual EGFR/human epidermal growth factor receptor 2 inhibitors, succeeded by *in vitro* anticancer screening against the MDA-MB-231 cell line. All the hybrids showed the IC_{50} in the range of 0.36–40.90 μ M. Among these, compound

10 exhibited the highest EGFR inhibitory profile (63.00%) in compared to erlotinib (68.30%) [Figure 2]. The SAR analysis revealed that bulky groups linked to the acetamide moiety are necessary for biological activity. Furthermore, the results of the molecular docking analysis were paralleled with the results of the cytotoxicity study (PDB code: 1M17).^[39]

Thiazole, which is an active heterocycle,^[40-44] was combined with 4-(3H)-quinazolinone through molecular hybridization by Hosseinzadeh *et al.* These hybrid compounds were synthesized, succeeded by *in vitro* anticancer evaluation against three human cancer cell lines (MCF-7, PC-3, and HT-29). SAR consideration




Figure 2: Quinazolinone hybrids with anticancer activity




Figure 3: 4-Aminoquinazolinone- and sulfonamide-based hybrids




Figure 5: Azetidiny-quinazolinone hybrids

revealed the important role of the halogen group (Cl) at the 2th position. Among hybrids, compound 11 was active against three cell lines [Figure 2].^[45]

Considering the importance of benzimidazole as a biologically active heterocycle,^[46-48] Taherian *et al.* designed a unique series of quinazolinone-benzimidazole hybrids. After cytotoxic evaluation, compounds displayed remarkable cytotoxic activity against MCF7 and Hela cell lines. SAR analysis showed that alkyl substituent had more important effect than phenyl substituent at the 3th position. Notably, compound 12 was active with IC₅₀ 50 μM against the Hella cell line [Figure 2].^[49]

Triazole, triazine, and sulfone have shown to increase the activity of many bioactive backbones.^[50-52] Al-Romaizan *et al.* have designed and synthesized quinazolinone diones-based derivatives by attaching the triazole, triazine, and sulfone moiety on quinazolinone structure. Among three series of hybrids, triazine derivatives exhibited more potent activity than triazole and sulfone analogs. SAR consideration revealed the importance of phenyl substituent in comparison with other heterocycle compounds at the 4th position of triazine. Especially, structures 13a and 13b have shown the highest cytotoxic activity with an IC₅₀ = 2.52 ± 0.69 μM and 1.57 ± 0.06 μM against HEP-G2 and HCT116 cell lines, respectively [Figure 2].^[53]




Figure 4: Quinazolinone-sulfonamide hybrids




Figure 6: Thiadiazole-linked quinazolinone hybrid

Oxadiazole is a pharmacologically active backbone that appears in famous pharmaceutical drugs such as oxolamine (cough suppressant), butalamine (vasodilator), faspion (anxiolytic), and pleconaril (antiviral).^[54,55] Hence, Srinivas *et al.* have synthesized hybrid compounds based on oxadiazole-Isoxazole and quinazolinone. All derivatives exhibited good anticancer activity against four cancer cell lines (A549, MCF-7, MDA MB-231, and DU-145). Significantly compounds 14a and 14b showed potent activity on the DU-145 cell line with an IC₅₀ of 0.011 ± 0.001 μM and on A549 cell line with an IC₅₀ of 0.014 ± 0.0061, respectively [Figure 2]. SAR analysis showed that methoxy substituted derivatives have shown promising activity on four cancer cell lines.^[56]

ANTIBACTERIAL ACTIVITIES

Sulfonamide analogs had shown antibacterial activity.^[57] On the other hand, 4-amino and its *N*-anilinoquinazolines derivatives were famous for being as selective inhibitors of tyrosine kinase.^[58] Because of such points, Kumar *et al.* reported two new hybrids of quinazolinone and benzenesulfonamide derivatives by connecting the benzene sulfonamide moiety on 4-amino quinazolinone scaffold. Among the hybrid

analogs, compound 15b has shown more potent antimicrobial activity than 15a [Figure 3]. However, these molecules have not shown reasonable anticancer activity against two breast adenocarcinoma cell lines, MDA-MB-231 and MCF 7, maybe, because of the presence of oxazole ring.^[59]

Some derivatives of quinazolinone-sulfonamide hybrids (16a and 16b) were designed using glycine amino acid as a precursor through an efficient multistep synthetic procedure. Synthesized compounds were assayed by the microdilution method against bacterial and fungal strains. In general, the compounds had a greater effect on gram-positive bacteria. The most active scaffolds belong to category 16a, containing 4-chloro-phenyl and 3-bromophenyl substitutions at position N-3 of quinazolinone scaffold, respectively. SAR analysis showed that halogenated phenyl substituents (bromo, chloro, and fluoro) have a more significant effect on activity than nonhalogenated phenyl substituents (nitro, methoxy, and methyl). Compounds with substitutions mentioned in Figure 4 indicated good activity against both the fungal species, including *Aspergillus niger* than *Candida albicans* [Figure 4].^[60]

Azetidinone ring is found as the primary fragments in many of natural and synthetic compounds.^[61] The presence azetidinone ring in essential antibiotics such as cephalosporins, thienamycins, and penicillins highlighted

the importance of this ring in medicinal chemistry research. Myangar and Raval have designed and synthesized azetidiny quinazolinone hybrid derivatives. Then, these molecules were checked for *in vitro* antibacterial and antifungal screening. Molecule 17 [Figure 5] demonstrates potent antitubercular activity. The antibacterial activity data exhibit that the derivatives with electron-withdrawing substituents (halogen and nitro) showed better to moderate activity. In contrast, analogs containing chloro and methoxyl substituent indicated better antifungal activities.^[62]

OTHER PHARMACOLOGICAL ACTIVITIES

Urease is a metalloenzyme that plays a valuable role in the hydrolysis of urea. This reaction occurs in two steps and produces ammonia and carbamate. Spontaneously carbamate hydrolyzes to carbonic acid and ammonia.^[63] This hydrolysis phenomena increase pH, which causes *Helicobacter pylori* to survive.^[64] As mentioned in the articles, triazole, thiadiazole, and semicarbazones have shown urease inhibition.^[65,66] Hence, in the search for potent urease inhibitors, Mentese




Figure 7: Dihydroquinazoline-benzamide hybrid




Figure 9: Quinazoline-thiazoline hybrid




Figure 8: Hydrazine-linked quinazolinone hybrid




Figure 10: Sulfonamide-linked quinazolinones

et al. synthesized five series hybrid compounds by the connecting of quinazolinone with thiadiazole, triazole, and thiosemicarbazide. Then, these compounds evaluated their *in vitro* urease inhibition characteristics. Among five series of hybrids, thiadiazole derivatives exhibited for their more potent activity than other analogs. SAR analysis showed that halogenated phenyl substituents (fluoro) at position-2 had more potent inhibitor activity than other substituents, and compound 18 has especially shown the most activity with an IC_{50} value of $1.88 \pm 0.17 \mu\text{g}/\text{mL}$ [Figure 6]. Furthermore, docking simulation results of these compounds with *Jack bean* urease (PDB ID: 3LA4) have shown a good correlation of *Jack bean* urease inhibition with the experimental results.^[67]

Inhibition of COX enzyme (which plays a significant role in prostaglandin biosynthesis) can cause analgesic effects.^[68] Proquazone and fluproquazone are two well-known nonsteroidal anti-inflammatory drug (NSAIDs) that contain a quinazolinone scaffold.^[69,70] Due to the anti-inflammatory and analgesic activities of quinazolinone and in the search for effective COX-1/2 inhibitors, Sakr *et al.* have synthesized a unique series of dihydro quinazoline-benzamide hybrids. These molecules have been assayed for their anti-inflammatory, analgesic, gastric ulcerogenic, and COX-1/2 inhibitory activity. For this purpose, two neighboring phenyl rings are linked to a primary heterocyclic moiety (quinazolinone) at 2 and 3 positions (V-shape). Furthermore, a linker (ester or amide) between one of the phenyl rings and the primary heterocycle (quinazolinone) can improve COX-2 selectivity. Otherwise, carboxylic acid, sulfonyl, and sulfonamide groups were seen in traditional NSAIDs which were removed. Among all the synthesized hybrids, compound 19 exhibited the most excellently biological activity in all the tests [Figure 7]. SAR consideration indicated the critical role of the substitution (nitro, chloride, methoxy, and fluoride groups) in both phenyl rings. Furthermore, the results of the docking analysis were compared with the results of the experimental study (PDB ID: 1CX2).^[70]

Alzheimer's disease (AD) is a modern neurodegenerative disease that causes dementia. BACE1 plays a vital role in AD.^[71,72] Hence, in the explore for AD therapy, Haghighijoo *et al.* synthesized hybrid compounds containing quinazolinone and hydrazone moieties as BACE1 inhibitors. Among the synthesized analogs, compound 20 has shown promising activity against BACE1 ($IC_{50} = 3.7 \mu\text{M}$) [Figure 8]. SAR consideration exhibited that the small H-bond donors (OH group) in phenyl ring improve the inhibitory activity. Furthermore, the addition of two chlorine atoms on the phenyl moiety improves the inhibitory activity. Furthermore, the results of the docking analysis with

BACE1 (PDB code: 4B70) exhibited the lowest binding energy and high docking score.^[73]

DPP-4 is a protease enzyme that inactivates glucose-dependent insulin tropic polypeptide and glucagon-like peptide 1. DPP-4 inhibitors play vital roles in maintaining glucose homeostasis.^[74] By considering the antidiabetic activities of quinazolinone and thiazoline scaffolds, Ali *et al.* synthesized some of the thiazoline-linked quinazolinones hybrids by multistep reactions starting from anthranilic acid. Target compounds were assayed for their *in vitro* DPP-4 inhibitory activity, *in vivo* antidiabetic activity, and (1,1-diphenyl-2-picrylhydrazyl) radical scavenging properties. Due to the great activity of compound 21 [Figure 9] in DPP-4 enzyme inhibition ($IC_{50} = 0.76 \text{ nM}$), it could be used as a lead compound for developing new antidiabetic agents. Compound 21 with score value -6.27 displayed better binding interaction to DPP-IV (PDB Code: 2RGU).^[75]

Some derivatives of sulfonamide-linked quinazolinones were prepared by ionic liquid-mediated stereoselective synthesis. These compounds were evaluated for their antimalarial potency. Compound 22, shown in Figure 10, was determined to be active antimalarial agents ($IC_{50} = 0.068 \mu\text{g}/\text{mL}$) as compared to standard drugs. Docking results against the enzymes human DHFR and *Plasmodium falciparum* DHFR confirmed *in vitro* evaluations.^[76]

CONCLUSION

Due to biologically activities of hybrid compounds of quinazolinones/quinazolinone, these heterocycles are an essential backbone in the range of synthetic compounds. Molecular hybridization is a new technique for combining one or more small molecules in one molecule to introduce new pharmacologically active lead compounds. This review covered important diseases, such as diabetes, Alzheimer, microbial infections, and cancer. The purpose of this review is to illustrate the biological activity of quinazolinone and quinazolinone-based hybrids for the development of new therapeutic agents.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Armarego WL. A Text Book of Quinazolines. *Adv Heterocycle Chem.* 1963;1:253-309.
2. Ranawat MS, Amrutkar SV, Phargharmol P. Synthesis and pharmacological evaluation of 3-alkyl/aryl-2-methylquinazolin-

- 4-one derivatives. *Int J Drug Des Discov* 2011;2:453-7.
3. Kidwai M, Rastog S, Mohan R. A novel route to the niementowski reaction. *Croat Chem Acta* 2003;76:365-9.
 4. Jafari E, Khajouei MR, Hassanzadeh H, Khodarahmi GA. Quinazolinone and quinazolin derivatives: recent structures with potent antimicrobial and cytotoxic activities 2016;11:1-14.
 5. Nasab RR, Karami B, Khodabakhshi S. Selective solvent-free biginelli condensation using tungstate sulfuric acid as powerful and reusable catalyst. *Bull Chem React Eng Catal* 2014;9:148-54.
 6. Mohammadkhani L, Heravi MM. Microwave-assisted synthesis of quinazolines and quinazolinones: An overview. *Front Chem* 2020;8:580086.
 7. Karaali N. A convenient method for the synthesis of 3,4-dihydroquinazolines from iminoester hydrochlorides via microwave irradiation. *J Chem Res* 2019;43:140-3.
 8. Auti PS, George G, Paul AT. Recent advances in the pharmacological diversification of quinazolinone/quinazolinone hybrids. *RSC Adv* 2020;10:41353.
 9. Hameed A, Al-Rashida M, Uroos M, Ali SA, Arshia, Ishtiaq M, *et al.* Quinazolinone and quinazolinone as important medicinal scaffolds: A comparative patent review (2011-2016). *Expert Opin Ther Pat* 2018;28:281-97.
 10. Chandrika PM, Yakaiah T, Rao AR, Narsaiah B, Reddy NC, Sridhar V, *et al.* Synthesis of novel 4,6-disubstituted quinazolinone derivatives, their anti-inflammatory and anti-cancer activity (cytotoxic) against U937 leukemia cell lines. *Eur J Med Chem* 2008;43:846-52.
 11. Nasab RR, Hassanzadeh F, Khodarahmi GA, Mirzaei M, Rostami M, Jahanian Najaf Abadi A. Synthesis, characterization, cytotoxic screening, and density functional theory studies of new derivatives of quinazolin-4(3H)-one Schiff bases. *Res Pharm Sci* 2017;12:444-55.
 12. Alagarsamy V, Meena S, Ramaseshu KV, Solomon VR, Kumar TD, Thirumurugan K. Synthesis of novel 3-butyl-2-substituted amino-3H-quinazolin-4-ones as analgesic and anti-inflammatory agents. *Chem Biol Drug Des* 2007;70:254-60.
 13. Kuyper LF, Baccanari DP, Jones ML, Hunter RN, Tansik RL, Joyner SS, *et al.* High-affinity inhibitors of dihydrofolatereductase: Antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diamino pyrrolo[3,2-f]quinazolines with small molecular size. *J Med Chem* 1996;39:892-903.
 14. Nasab RR, Hassanzadeh F, Khodarahmi GA, Rostami M, Mirzaei M, Jahanian-Najafabadi A, *et al.* Docking study, synthesis and antimicrobial evaluation of some novel 4-anilinoquinazolinone derivatives. *Res Pharm Sci* 2017;12:425-33.
 15. Verhaeghe P, Azas N, Gasquet M, Hutter S, Ducros C, Laget M, *et al.* Synthesis and antiplasmodial activity of new 4-aryl-2-trichloromethylquinazolines. *Bioorg Med Chem Lett* 2008;18:396-401.
 16. Rosowsky A, Wright JE, Vaidya CM, Forsch RA. The effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolatereductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine. *Pharmacol Ther* 2000;85:191-205.
 17. Garofalo A, Goossens L, Lemoine A, Ravez S, Six P, Howsam M, *et al.* [4-(6,7-Disubstituted quinazolin-4-ylamino) phenyl] carbamic acid esters: A novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors. *RSC Med Chem* 2011;2:65-72.
 18. Ivasiv V, Albertini C, Gonçalves AE, Rossi M, Bolognesi ML. Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases. *Curr Top Med Chem* 2019;19:1694-711.
 19. Abbot V, Sharma P, Dhiman S, Noolvi MN, Patel HM, Bhardwaj V. Small hybrid heteroaromatics: Resourceful biological tools in cancer research. *RSC Adv* 2017;7:28313-49.
 20. Kerru N, Singh P, Koorbanally N, Raj R, Kumar V. Recent advances (2015-2016) in anticancer hybrids. *Eur J Med Chem* 2017;142:179-212.
 21. Khan I, Zaib S, Batool S, Abbas N, Ashraf Z, Iqbal J, *et al.* Quinazolines and quinazolinones as ubiquitous structural fragments in medicinal chemistry: An update on the development of synthetic methods and pharmacological diversification. *Bioorg Med Chem* 2016;24:2361-81.
 22. Hassanzadeh F, Sadeghi-Aliabadi H, Jafari E, Sharifzadeh A, Dana N. Synthesis and cytotoxic evaluation of some quinazolinone-5-(4chlorophenyl)1,3,4-oxadiazole conjugates. *Res Pharm Sci* 2019;14:408-13.
 23. Hassanzadeh F, Sadeghi-Aliabadi H, Nikooei S, Jafari E, Vaseghi G. Synthesis and cytotoxic evaluation of some derivatives of triazole-quinazolinone hybrids. *Res Pharm Sci* 2019;14:130-7.
 24. Patel RV, Park SW. An evolving role of piperazine moieties in drug design and discovery. *Mini Rev Med Chem* 2013;13:1579-601.
 25. Zhang Y, Yang CR, Tang X, Cao SL, Ren TT, Gao M, *et al.* Synthesis and antitumor activity evaluation of quinazolinone derivatives bearing piperazine-1-carbodithioate moiety at C4-position. *Bioorg Med Chem Lett* 2016;26:4666-70.
 26. Xia Y, Yang ZY, Hour MJ, Kuo SC, Xia P, Bastow KF, *et al.* Antitumor agents. Part 204: Synthesis and biological evaluation of substituted 2-aryl quinazolinones. *Bioorg Med Chem Lett* 2001;11:1193-6.
 27. Thurston DE. *Molecular Aspects of Anticancer Drug DNA Interactions*. London, UK: The Macmillan Press Ltd; 1993. p. 54-88.
 28. Kamal A, Vijaya Bharathi E, Janaki Ramaiah M, Dastagiri D, Surendranadha Reddy J, Viswanath A, *et al.* Quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates: Design, synthesis and biological evaluation as potential anticancer agents. *Bioorg Med Chem* 2010;18:526-42.
 29. Vodnala S, Bhavani AK, Kamutam R, Naidu VG, Promila, Prabhakar Ch. DABCO-catalyzed one-pot three component synthesis of dihydropyrano[3,2-c]chromene substituted quinazolines and their evaluation towards anticancer activity. *Bioorg Med Chem Lett* 2016;26:3973-7.
 30. Kamal A, Tamboli JR, Ramaiah MJ, Adil SF, Pushpavalli SN, Ganesh R, *et al.* Quinazolinone linked 4β-amidopodophyllotoxin conjugates regulate angiogenic pathway and control breast cancer cell proliferation. *Bioorg Med Chem* 2013;21:6414-26.
 31. Asadi P, Khodarahmi G, Jahanian-Najafabadi A, Saghaie L, Hassanzadeh F. Synthesis, characterization, molecular docking studies and biological evaluation of some novel hybrids based on quinazolinone, benzofuran and imidazolium moieties as potential cytotoxic and antimicrobial agents. *Iran J Basic Med Sci* 2017;20:975-89.
 32. Murray M, Hraiki A, Bebawy M, Pazderka C, Rawling T. Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs. *Pharmacol Ther* 2015;150:109-28.
 33. Kostadinova A, Topouzova-Hristova T, Momchilova A, Tzoneva R, Berger MR. Chapter two – Antitumor lipids – Structure, functions, and medical applications. *Adv Protein Chem Struct Biol* 2015;101: 27-66.
 34. Pachioni Jde A, Magalhães JG, Lima EJ, Bueno Lde M, Barbosa JF, de Sá MM, *et al.* Alkylphospholipids – A promising class of chemotherapeutic agents with a broad pharmacological spectrum. *J Pharm Pharm Sci* 2013;16:742-59.
 35. Clive S, Gardiner J, Leonard RC. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. *Cancer Chemother Pharmacol* 1999;44(Suppl):S29-30.
 36. Alam MM, Hassan AH, Kwon YH, Lee HJ, Kim NY, Min KH, *et al.*

- Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents. *Arch Pharm Res* 2018;41:35-45.
37. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. *Nat Rev Cancer* 2010;10:760-74.
 38. Alam MM, Hassan AH, Lee KW, Cho MC, Yang JS, Song J, *et al.* Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. *Bioorg Chem* 2019;84:51-62.
 39. Ghorab MM, Alsaid MS, Soliman AM. Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g] quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers. *Bioorg Chem* 2018;80:611-20.
 40. Bharti SK, Nath G, Tilak R, Singh SK. Synthesis, anti-bacterial and anti-fungal activities of some novel Schiff bases containing 2,4-disubstituted thiazole ring. *Eur J Med Chem* 2010;45:651-60.
 41. Khalil AM, Berghot MA, Gouda MA. Synthesis and antibacterial activity of some new thiazole and thiophene derivatives. *Eur J Med Chem* 2009;44:4434-40.
 42. Pandeya SN, Sriram D, Nath G, DeClercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4'-chlorophenyl) thiazol-2-yl] thiosemicarbazide. *Eur J Pharm Sci* 1999;9:25-31.
 43. Cukurovali A, Yilmaz I, Gur S, Kazaz C. Synthesis, antibacterial and antifungal activity of some new thiazolyldrazone derivatives containing 3-substituted cyclobutane ring. *Eur J Med Chem* 2006;41:201-7.
 44. Li J, Xu Z, Tan M, Su W, Gong XG. 3-(4-(Benzo[d]thiazol-2-yl)-1-phenyl-1H-pyrazol-3-yl) phenyl acetate induced Hep G2 cell apoptosis through a ROS-mediated pathway. *Chem Biol Interact* 2010;183:341-8.
 45. Hosseinzadeh L, Aliabadi A, Kalantari M, Mostafavi A, Khajouei MR. Synthesis and cytotoxicity evaluation of some new 6-nitro derivatives of thiazole-containing 4-(3H)-quinazolinone. *Res Pharm Sci* 2016;11:210-8.
 46. Zohdi HF, Rateb NM, Khlosy TA. Synthesis, reaction and antimicrobial activity of some pyridinethione derivatives containing benzimidazole nucleus. *Int J Adv Res* 2014;2:861-72.
 47. Dawood K, Elwan N, Farahat A, Abdel-Wahab B. 1H-Benzimidazole-2-acetonitriles as synthon in fused benzimidazole synthesis. *J Heterocycl Chem* 2010;47:243-89.
 48. Mavrova AT, Vuchev D, Anichina K, Vassilev N. Synthesis, antitrichinellosis and antiprotozoal activity of some novel thieno[2,3-d]pyrimidin-4(3H)-ones containing benzimidazole ring. *Eur J Med Chem* 2010;45:5856-61.
 49. Taherian E, Khodarahmi G, Khajouei MR, Hassanzadeh F, Dana N. Synthesis and cytotoxic evaluation of novel quinozaline derivatives with substituted benzimidazole in position 3. *Res Pharm Sci* 2019;14:247-54.
 50. El-Reedy AA, Soliman NK. Synthesis, biological activity and molecular modeling study of novel 1,2,4-triazolo[4,3-b][1,2,4,5] tetrazines and 1,2,4-triazolo[4,3-b][1,2,4]triazines. *Sci Rep* 2020;10:6137.
 51. Arshad M, Khan TA, Khan MA. 1,2,4-triazine derivatives: Synthesis and biological applications. *IJPSR* 2014;5:149-62.
 52. Ahmad I, Shagufta W. Sulfones: An important class of organic compounds with diverse biological activities. *IJPSR* 2015;7:19-27.
 53. Al-Romaizan AN, Ahmed NS, Elfeky SM. Design, synthesis, and biological evaluation of triazolyl- and triazinyl-quinazolinones as potential antitumor agents. *J Chem* 2019;2019:1-12.
 54. Vaidya A, Jain S, Jain P, Tiwari N, Jain R, *et al.* Synthesis and biological activities of oxadiazole derivatives: A review. *Mini Rev Med Chem* 2016;16:825.
 55. Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. *Annu Rev Med* 2013;64:407-25.
 56. Srinivas M, Satyaveni S, Ram B. Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-isoxazole linked quinazoline derivatives as anticancer agents. *Russ J Gen Chem* 2019;89:2492.
 57. Ozbek N, Katircioğlu H, Karacan N, Baykal T. Synthesis, characterization and antimicrobial activity of new aliphatic sulfonamide. *Bioorg Med Chem* 2007;15:5105-9.
 58. Berger M, Albrecht B, Berces A, Etmayer P, Neruda W, Woisetschlager M. S(+)-4-(1-Phenylethylamino) quinazolines as inhibitors of human immunoglobulin E synthesis: Potency is dictated by stereochemistry and atomic point charges at N-1. *J Med Chem* 2001;44:3031-8.
 59. Kumar AS, Kudva J, Kumar SM, Vishwanatha U, Kumar V, Naral D. Synthesis, characterization, crystal structure, Hirshfeld interaction and bio-evaluation studies of 4-amino quinazoline sulfonamide derivatives. *J Mol Struct* 2018;1167:142-53.
 60. Vanparia SF, Patel TS, Dixit RB, Dixit BC. Synthesis and *in vitro* antimicrobial activity of some newer quinazolinone-sulfonamide linked hybrid heterocyclic entities derived from glycine. *Med Chem Res* 2013;22:5184-96.
 61. Singh GS. Recent progress in the synthesis and chemistry of azetidiones. *Tetrahedron* 2003;59:7631-49.
 62. Myangar KN, Raval JP. Design, synthesis, and *in vitro* antimicrobial activities of novel azetidiny-3-quinazolin-4-one hybrids. *Med Chem Res* 2012;21:2762-71.
 63. Zambelli B, Musiani F, Benini S, Ciurli S. Chemistry of Ni²⁺ in urease: Sensing, trafficking, and catalysis. *Acc Chem Res* 2011;44:520-30.
 64. Mobley HL, Hausinger RP. Microbial ureases: Significance, regulation, and molecular characterization. *Microbiol Rev* 1989;53:85-108.
 65. Akhtar T, Hameed S, Khan KM, Khan A, Choudhary MI. Design, synthesis, and urease inhibition studies of some 1,3,4-oxadiazoles and 1,2,4-triazoles derived from mandelic acid. *J Enzyme Inhib Med Chem* 2010;25:572-6.
 66. Delgado JN, Remers WA. Wilson Gisvold's Textbook of Organic, Medicinal and Pharmaceutical Chemistry. Philadelphia: Lippincott Williams & Wilkins; 10th ed; 1998.
 67. Mentese E, Akyüz G, Emirik M, Baltaş N. Synthesis, *in vitro* urease inhibition and molecular docking studies of some novel quinazolin-4(3H)-one derivatives containing triazole, thiadiazole and thiosemicarbazide functionalities. *Bioorg Chem* 2019;83:289-96.
 68. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. *J Med Chem* 2007;50:1425-41.
 69. Chandrika P, Rao AR, Narsaiah B, Raju M. Quinazoline derivatives with potent anti-inflammatory and anti-allergic activities. *Int J Chem Sci* 2008;6:1119-46.
 70. Sakr A, Kothayer H, Ibrahim SM, Baraka MM, Rezaq S. 1,4-Dihydroquinazolin-3(2H)-yl benzamide derivatives as anti-inflammatory and analgesic agents with an improved gastric profile: Design, synthesis, COX-1/2 inhibitory activity and molecular docking study. *Bioorg Chem* 2019;84:76-86.
 71. Zhou L, Chávez-Gutiérrez L, Bockstael K, Sannerud R, Annaert W, May PC, *et al.* Inhibition of β -secretase *in vivo* via antibody binding to unique loops (D and F) of BACE1. *J Biol Chem* 2011;286:8677-87.
 72. Ghosh AK, Brindisi M, Tang J. Developing β -secretase inhibitors for treatment of Alzheimer's disease. *J Neurochem* 2012;120 Suppl 1:71-83.

73. Haghijoo Z, Firuzi O, Hemmateenejad B, Emami S, Edraki N, Miri R. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease. *Bioorg Chem* 2017;74:126-33.
74. Demuth HU, McIntosh CH, Pederson RA. Type 2 diabetes – Therapy with dipeptidyl peptidase IV inhibitors. *Biochim Biophys Acta* 2005;1751:33-44.
75. Ali Z, Akhtar MJ, Haider MR, Khan AA, Siddiqui AA, Yar MS. Design and synthesis of quinazoline-3,4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor. *Bioorg Chem* 2017;71:181-91.
76. Patel TS, Bhatt JD, Vanparia SF, Patel UH, Dixit RB, Chudasama CJ, *et al.* Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway. *Bioorg Med Chem* 2017;25:6635-46.